GS-3242

**GS-3242** is a long-acting, investigational **integrase strand transfer inhibitor (INSTI)** designed for the treatment of HIV infection. It is being developed by **Gilead Sciences** with the aim of providing extended dosing intervals (potentially up to every six months) as an injectable therapy for HIV. GS-3242 inhibits the HIV integrase enzyme, blocking the integration of viral DNA into the host cell genome, a critical step in the HIV replication cycle. As of the latest public information, GS-3242 has not progressed beyond preclinical or early clinical development, with no current approval or finalized clinical data. Its primary indication is HIV infection, and it is being studied primarily as part of next-generation long-acting antiretroviral regimens[1][3][5][7][9].